Technical Analysis for BGNE - BeiGene, Ltd.
|Grade||Last Price||% Change||Price Change|
BGNE closed up 0.12 percent on Friday, August 17, 2018, on 40 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Up||Down||Down|
|See historical BGNE trend table...|
|Date||Alert Name||Type||% Chg|
|Aug 17||Lower Bollinger Band Walk||Weakness||0.00%|
|Aug 17||Multiple of Ten Bearish||Other||0.00%|
|Aug 17||Oversold Stochastic||Weakness||0.00%|
|Aug 16||NR7||Range Contraction||0.12%|
|Aug 16||Doji - Bullish?||Reversal||0.12%|
|Aug 16||Lower Bollinger Band Walk||Weakness||0.12%|
|Aug 16||Multiple of Ten Bearish||Other||0.12%|
|Aug 16||Lower Bollinger Band Touch||Weakness||0.12%|
|Aug 16||Oversold Stochastic||Weakness||0.12%|
|Aug 15||180 Bearish Setup||Bearish Swing Setup||-0.23%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BGNE news...
|52 Week High||220.1|
|52 Week Low||65.67|
|200-Day Moving Average||145.3678|
|50-Day Moving Average||169.586|
|20-Day Moving Average||171.4525|
|10-Day Moving Average||166.038|
|Average True Range||8.1716|
|Chandelier Exit (Long, 3 ATRs )||170.0452|
|Chandelier Exit (Short, 3 ATRs )||179.5248|
|Upper Bollinger Band||189.0367|
|Lower Bollinger Band||153.8683|
|Percent B (%b)||0.1|
|MACD Signal Line||-1.0534|
|Market Cap||6.27 Billion|
|Num Shares||39.8 Million|
|Price-to-Earnings (P/E) Ratio||-31.65|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||166.86|
|Resistance 3 (R3)||167.32||164.60||165.27|
|Resistance 2 (R2)||164.60||162.17||164.37||164.74|
|Resistance 1 (R1)||160.96||160.67||159.60||160.50||164.21|
|Support 1 (S1)||154.60||155.81||153.24||154.14||150.43|
|Support 2 (S2)||151.88||154.31||151.65||149.90|
|Support 3 (S3)||148.24||151.88||149.37|
|Support 4 (S4)||147.78|